Condensed Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Total revenues	$ 0	$ 0
Total cost of revenue	0	0
Gross loss	0	0
Research and development expense	1,645,000	1,464,000
Selling, general and administrative expense	1,639,000	1,481,000
Operating loss	(2,981,000)	(4,454,000)
Other income (expense):
Warrant revaluation income (expense)	235,000	(46,000)
Derivative revaluation expense	(63,000)	(312,000)
Interest expense	(190,000)	(183,000)
Other income (expense), net	98,000	(12,000)
Loss before income taxes	(2,901,000)	(5,007,000)
Income taxes	0	0
Net loss	(2,901,000)	(5,007,000)
Dividend paid in-kind to preferred stockholders	(82,000)	(20,000)
Deemed dividend on preferred stock (see Note 10)	(121,000)	(3,734,000)
Net loss attributable to common stockholders	$ (3,104,000)	$ (8,761,000)
Per Share Information:
Basic net loss (usd per share)	$ (0.11)	$ (0.60)
Diluted net loss (usd per share)	$ (0.11)	$ (0.60)
Weighted average number of common shares outstanding:
Basic weighted average number of common shares outstanding (shares)	28,356,351	14,694,613
Diluted weighted average number of common shares outstanding (shares)	28,356,351	14,697,210
Affiliated Entity
Research and development expense	$ (303,000)	$ 1,509,000